| Michael Ross Driedger, MD | |
|
200 Medical Park Dr, Ste 430, Concord, NC 28025-2982 | |
| (704) 403-5890 | |
| Not Available |
| Full Name | Michael Ross Driedger |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 11 Years |
| Location | 200 Medical Park Dr, Concord, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508344805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086X0206X | Surgery - Surgical Oncology | 2020-03350 (North Carolina) | Secondary |
| 208600000X | Surgery | 2020-03350 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carolinas Medical Center-northeast | Concord, NC | Hospital |
| Carolinas Medical Center/behav Health | Charlotte, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolinas Physicians Network Inc | 3375449655 | 1613 |
| Carolinas Medical Center | 4789597477 | 735 |
News Archive
More than 4 million people living with HIV in low- and middle-income countries had access to life-saving antiretroviral therapy (ART) by the end of 2008, according to a report released Wednesday by the WHO, UNICEF and UNAIDS, the Associated Press reports.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
This report, titled "Improving Women's Heath in South Africa: Opportunities for PEPFAR," by Janet Fleischman of the Center for Strategic and International Studies, says that with "major change ... unfolding in health and HIV services in South Africa," "[t]he United States can find feasible, flexible ways to support" the decentralization of "HIV services to the primary care level ... even though its health program through the President's Emergency Plan for AIDS Relief (PEPFAR) is scaling down.
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.
ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.
› Verified 9 days ago
| Entity Name | Carolinas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774333 PECOS PAC ID: 4789597477 Enrollment ID: O20031110000116 |
News Archive
More than 4 million people living with HIV in low- and middle-income countries had access to life-saving antiretroviral therapy (ART) by the end of 2008, according to a report released Wednesday by the WHO, UNICEF and UNAIDS, the Associated Press reports.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
This report, titled "Improving Women's Heath in South Africa: Opportunities for PEPFAR," by Janet Fleischman of the Center for Strategic and International Studies, says that with "major change ... unfolding in health and HIV services in South Africa," "[t]he United States can find feasible, flexible ways to support" the decentralization of "HIV services to the primary care level ... even though its health program through the President's Emergency Plan for AIDS Relief (PEPFAR) is scaling down.
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.
ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.
› Verified 9 days ago
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437607686 PECOS PAC ID: 3375449655 Enrollment ID: O20040115000819 |
News Archive
More than 4 million people living with HIV in low- and middle-income countries had access to life-saving antiretroviral therapy (ART) by the end of 2008, according to a report released Wednesday by the WHO, UNICEF and UNAIDS, the Associated Press reports.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
This report, titled "Improving Women's Heath in South Africa: Opportunities for PEPFAR," by Janet Fleischman of the Center for Strategic and International Studies, says that with "major change ... unfolding in health and HIV services in South Africa," "[t]he United States can find feasible, flexible ways to support" the decentralization of "HIV services to the primary care level ... even though its health program through the President's Emergency Plan for AIDS Relief (PEPFAR) is scaling down.
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.
ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.
› Verified 9 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
More than 4 million people living with HIV in low- and middle-income countries had access to life-saving antiretroviral therapy (ART) by the end of 2008, according to a report released Wednesday by the WHO, UNICEF and UNAIDS, the Associated Press reports.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
This report, titled "Improving Women's Heath in South Africa: Opportunities for PEPFAR," by Janet Fleischman of the Center for Strategic and International Studies, says that with "major change ... unfolding in health and HIV services in South Africa," "[t]he United States can find feasible, flexible ways to support" the decentralization of "HIV services to the primary care level ... even though its health program through the President's Emergency Plan for AIDS Relief (PEPFAR) is scaling down.
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.
ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Ross Driedger, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Michael Ross Driedger, MD 200 Medical Park Dr, Ste 430, Concord, NC 28025-2982 Ph: (704) 403-5890 |
News Archive
More than 4 million people living with HIV in low- and middle-income countries had access to life-saving antiretroviral therapy (ART) by the end of 2008, according to a report released Wednesday by the WHO, UNICEF and UNAIDS, the Associated Press reports.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
This report, titled "Improving Women's Heath in South Africa: Opportunities for PEPFAR," by Janet Fleischman of the Center for Strategic and International Studies, says that with "major change ... unfolding in health and HIV services in South Africa," "[t]he United States can find feasible, flexible ways to support" the decentralization of "HIV services to the primary care level ... even though its health program through the President's Emergency Plan for AIDS Relief (PEPFAR) is scaling down.
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.
ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.
› Verified 9 days ago
Jacqueline Tracey, Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Park Dr, Suite 430, Concord, NC 28025 Phone: 704-403-7070 | |
Medhat William Takla, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Park Dr, Ste 230, Concord, NC 28025 Phone: 704-403-1349 | |
Matthew David Fox, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Park Dr, Ste 430, Concord, NC 28025 Phone: 704-403-7070 | |
Laura Elizabeth Hudson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Park Dr Ste 400, Concord, NC 28025 Phone: 704-786-1108 Fax: 704-782-1826 | |
Jennifer Brooke Hale, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 920 Church St N, Concord, NC 28025 Phone: 704-403-1311 | |
Michael Joseph Beckman, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Park Dr, Ste 430, Concord, NC 28025 Phone: 704-403-5890 | |
Anthony Stallion, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 100 Medical Park Dr, Suite 310, Concord, NC 28025 Phone: 704-403-2662 Fax: 704-403-2670 |